Liver cirrhosis clinical trial pipeline is growing globally, with advancements in treatment options
From GlobeNewswire: 2025-01-15 13:00:00
Liver Cirrhosis Clinical Trial Pipeline is gaining momentum globally, with over 30 companies actively working in the field. The market is set for growth due to lifestyle factors like obesity and alcohol consumption, resulting in a rise in liver diseases. Technological advancements and an aging population are driving demand for improved treatments.
The Liver Cirrhosis Pipeline Insight 2025 report by DelveInsight highlights key players like Versantis AG, Mirum Pharmaceuticals, and Sagimet Biosciences working on new drugs to enhance treatment options. Promising therapies such as Volixibat and VS-01 are undergoing clinical trials, showing potential for advanced liver cirrhosis treatment.
In recent clinical trials, Galectin Therapeutics announced positive results for belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis, while Lipocine presented Phase II results on LPCN 1148. Resolution Therapeutics also showcased the potential of macrophage cell therapy for advanced liver cirrhosis. Other companies are advancing their pipeline of liver cirrhosis drugs to meet the growing demand.
Liver Cirrhosis is a condition where the liver becomes scarred and loses functionality due to long-term damage. Symptoms include fatigue, swelling, and itching. Diagnosis involves blood tests, imaging, and sometimes a liver biopsy. Treatment focuses on managing symptoms, preventing complications, and addressing underlying causes through lifestyle changes and medication.
The Liver Cirrhosis Pipeline Report provides a comprehensive overview of emerging therapies segmented by stage, product type, route of administration, and mechanism of action. Key companies like Mirum Pharmaceuticals and Resolution Therapeutics are developing innovative treatments like Volixibat and RTX-001 to address the unmet needs in liver cirrhosis management.
For more insights on liver cirrhosis drugs and clinical trials, visit DelveInsight’s website. The report covers late-stage, mid-stage, and early-stage products, offering a detailed assessment of the liver cirrhosis pipeline landscape. Companies like PharmaIN and Lipocine are making significant progress in developing new treatments for liver cirrhosis.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with them on LinkedIn for more updates on liver cirrhosis and other healthcare advancements.
Read more at GlobeNewswire: Liver Cirrhosis Clinical Trial Pipeline Experiences